Newsbot

Gold and Silver Storm to Records as Fed Hit With Subpoenas

Gold and silver climbed to records in a broad-based metals rally as the US Justice Department threatened the Federal Reserve with a criminal indictment, reviving concerns over the central bank’s independence.

Investors focus on Fed independence as chair decision looms

When it comes to your money, the chair of the Federal Reserve has more power than you might think. Credit cards? Check.Student loans? Check.Auto loans? Check. Then there’s the impact on mortgage rates, your stock portfolio, and regulation of the nation’s banking industry.  Add the U.S. money ...

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Richard Francis, Tevas President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Tevas President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)

China’s PE Trailblazer Hopu Faces Doubts on Returns, Succession

As Fang Fengleis Hopu Investment Management seeks $1.5 billion to $2 billion for a new flagship fund, longtime backers including Temasek and CIC are reconsidering whether to invest after years of middling returns and leadership churn.

Zymeworks Outlines Strategic Priorities and Outlook for 2026

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patient...

Inside Starbucks’ bold plan to reclaim its magic

After roughly 15 months of the Covid pandemic lockdowns, I sat with my laptop outside a Starbucks in West Palm Beach. It seemed like a little thing, but when I realized how long I had been surviving off of drive-thru and pickup, I started to cry. Writing at Starbucks, or sometimes local coffee ...

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides prel...

Record Revenue And Backlog Volatility Might Change The Case For Investing In MasTec (MTZ)

In recent trading, MasTec reported record third-quarter revenue and a larger backlog, yet management cautioned that permitting delays and shifting customer spending can cause significant quarter-to-quarter swings in margins and cash flow.This mix of strong activity and operational uncertainty highlights how timing issues in major infrastructure projects can materially influence MasTec’s near-term financial profile.Next, we’ll examine how these permitting and spending-related margin swings...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides pr...

52-year-old restaurant closes as owners make heartfelt plea

My grandfather bought the land where our family business, Lynn Ladder & Scaffolding, still operates. Thats a prescient move that provides protection against business slowdowns and having your location sold out from underneath you. Its likely that our 80-year-old family business, which mostly ...